Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  NASDAQ OMX COPENHAGEN  >  Genmab A/S    GMAB   DK0010272202

GENMAB A/S

(GMAB)
  Report
Delayed Quote. Delayed NASDAQ OMX COPENHAGEN - 11/27 10:59:53 am
2319 DKK   +0.52%
11/25NOVARTIS : Genmab Announces Enapotamab Vedotin Update
AQ
11/24GENMAB A/S : Announces Enapotamab Vedotin Update
AQ
11/24GENMAB A/S : Announces Enapotamab Vedotin Update
AQ
SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations
Most relevant news about GENMAB A/S
11/25NOVARTIS : Genmab Announces Enapotamab Vedotin Update
AQ
11/24GENMAB A/S : Announces Enapotamab Vedotin Update
AQ
11/24GENMAB A/S : Announces Enapotamab Vedotin Update
AQ
11/24Genmab Announces Enapotamab Vedotin Update
GL
11/24GENMAB A/S : Mereo BioPharma Group plc - Mereo BioPharma Appoints Suba Krishnan,..
AQ
11/20IMMUNOPRECISE ANTIBODIES : and Genmab Enter into a Technology Partnership Target..
AQ
11/13GENMAB A/S : 2020 Virtual Capital Markets Day – November 13, 2020
PU
11/11GENMAB A/S : Articles of association dated November 10, 2020 – English
PU
11/11NOVARTIS : Capital Increase in Genmab as a Result of Employee Warrant Exercise
AQ
11/11NOVARTIS : Genmab to Present at Jefferies Virtual London Healthcare Conference
AQ
11/11GENMAB A/S : BioNTech Announces Third Quarter 2020 Financial Results and Corpora..
AQ
11/10GENMAB A/S : Capital Increase in Genmab as a Result of Employee Warrant Exercise
AQ
11/10GENMAB A/S : to Present at Jefferies Virtual London Healthcare Conference
AQ
11/06GENMAB A/S : Announces Phase 3 Study Evaluating Epcoritamab in Patients with Rel..
AQ
11/06GENMAB A/S : Announces that Janssen has submitted a Type II Variation Applicatio..
AQ
11/05GENMAB A/S : Announces Phase 3 Study Evaluating Epcoritamab in Patients with Rel..
AQ
11/05GENMAB A/S : Announces Phase 3 Study Evaluating Epcoritamab in Patients with Rel..
AQ
11/05Genmab Announces Phase 3 Study Evaluating Epcoritamab in Patients with Relaps..
GL
11/05GENMAB A/S : Announces that Janssen has Submitted a Type II Variation Applicatio..
AQ
11/04GENMAB A/S : Investor Presentation - November 2020
PU
11/04GENMAB A/S : Announces Financial Results for the First Nine Months of 2020
AQ
11/04GENMAB A/S : Announces Financial Results for the First Nine Months of 2020
AQ
11/04Genmab Announces Financial Results for the First Nine Months of 2020
GL
11/04GENMAB A/S : Announces Data to be Presented at 2020 ASH Annual Meeting
AQ
11/02ADC THERAPEUTICS : Genmab and ADC Therapeutics Announce Amended Agreement for Ca..
AQ
10/30GENMAB A/S : quaterly earnings release
10/30GENMAB A/S : and ADC Therapeutics Announce Amended Agreement for Camidanlumab Te..
AQ
10/22GENMAB A/S : Announces IFM, HOVON and Janssen Achieve Positive Topline Results i..
AQ
10/21GENMAB A/S : Announces IFM, HOVON and Janssen Achieve Positive Topline Results i..
AQ
10/21GENMAB A/S : Announces IFM, HOVON and Janssen Achieve Positive Topline Results i..
AQ
10/21Genmab Announces IFM, HOVON and Janssen Achieve Positive Topline Results in S..
GL
10/16GENMAB A/S : has published its Articles of Association
AQ
10/16NOVARTIS : Genmab to Host Capital Markets Day
AQ
10/15GENMAB A/S : Articles of association dated October 07, 2020 – English
PU
10/15GENMAB A/S : has published its Articles of Association
PU
10/15GENMAB A/S : to Host Capital Markets Day
AQ
10/15BioNTech to Present Data from BNT311 and BNT131 Programs at SITC 35th Annual ..
AQ
10/15Genmab Announces Data to be presented at SITC 35th Anniversary Annual Meeting
AQ
10/14GENMAB A/S : Announces Data to be Presented at SITC 35th Anniversary Annual Meet..
AQ
10/14GENMAB A/S : Announces Net Sales of DARZALEX for Third Quarter of 2020
AQ
10/13GENMAB A/S : Announces Net Sales of DARZALEX® (daratumumab) for Third Quarter of..
AQ
10/13GENMAB A/S : Announces Net Sales of DARZALEX® (daratumumab) for Third Quarter of..
AQ
10/13Genmab Announces Net Sales of DARZALEX® (daratumumab) for Third Quarter of 20..
GL
10/08NOVARTIS : Grant of Restricted Stock Units and Warrants to Employees in Genmab
AQ
10/07GENMAB A/S : Grant of Restricted Stock Units and Warrants to Employees in Genmab
AQ
10/01NOVARTIS : Transactions with shares and linked securities in Genmab A/S made by ..
AQ
10/01GENMAB A/S : has published its Articles of Association
AQ
09/30GENMAB A/S : Articles of association dated September 29, 2020 – English
PU
09/30NOVARTIS : Capital Increase in Genmab as a Result of Employee Warrant Exercise
AQ
09/30NOVARTIS : Transactions with shares and linked securities in Genmab A/S made by ..
AQ
09/29GENMAB A/S : Transactions with shares and linked securities in Genmab A/S made b..
AQ
09/29GENMAB A/S : Capital Increase in Genmab as a Result of Employee Warrant Exercise
AQ
09/23Genmab Commences Binding Arbitration of Two Matters under License Agreement w..
AQ
09/23EUROPE : Adidas, upbeat manufacturing PMIs lift European stocks
RE
09/23Genmab shares drop on legal battle with J&J over cancer drug
RE
09/23Travel rebound, Adidas support European stocks despite mixed data
RE
09/23Genmab shares drop on legal battle with J&J over cancer drug
RE
09/22GENMAB A/S : Commences Binding Arbitration of Two Matters Under License Agreemen..
AQ
09/22GENMAB A/S : Commences Binding Arbitration of Two Matters Under License Agreemen..
AQ
09/22Genmab Commences Binding Arbitration of Two Matters Under License Agreement w..
GL
09/21GENMAB A/S : and Seattle Genetics Present Data from Tisotumab Vedotin innovaTV 2..
AQ
09/21GENMAB A/S : and Seattle Genetics Present Data from Tisotumab Vedotin innovaTV 2..
AQ
09/21Genmab and Seattle Genetics Present Data from Tisotumab Vedotin innovaTV 204 ..
GL
09/10Genmab to Present at Morgan Stanley 18th Annual Global Healthcare Conference
AQ
09/10GENMAB A/S : Announces that Janssen has Submitted a Supplemental Biologics Licen..
AQ
09/09GENMAB A/S : to Present at Morgan Stanley 18th Annual Global Healthcare Conferen..
AQ
09/04AbbVie to develop and sell China-based I-Mab's cancer drug
RE
08/26GENMAB A/S : Announces Late-Breaking Oral Presentation of Phase 2 innovaTV 204 S..
AQ
08/21NOVARTIS : Genmab Announces Plan to Transition Arzerra to an Oncology Access Pro..
AQ
08/21GENMAB A/S : - U.S. FDA Approves Kesimpta in Relapsing Multiple Sclerosis
AQ
08/21GENMAB A/S : Announces Janssen Granted U.S. FDA Approval for DARZALEX in Combina..
AQ
08/20Genmab Announces Janssen Granted U.S. FDA Approval for DARZALEX® (daratumumab..
GL
08/20Genmab Announces Plan to Transition Arzerra® (ofatumumab) to an Oncology Acce..
GL
08/20Novartis wins FDA approval to repurpose leukaemia drug against multiple scler..
RE
08/20U.S. FDA Approves Kesimpta® (ofatumumab) in Relapsing Multiple Sclerosis
GL
1  2  3Next